Tybourne Capital Management (HK) Ltd has filed a Schedule 13G/A with the SEC, updating its ownership status in Forte Biosciences, Inc. This filing is significant as it reveals that Tybourne currently holds no beneficial ownership in the company.

The filing, submitted on November 4, 2026, indicates that Tybourne Capital Management, along with its affiliates, has not acquired any shares of Forte Biosciences. This absence of ownership may reflect a strategic decision as the firm reassesses its investment portfolio in the pharmaceutical preparations sector.

Background

Tybourne Capital Management (HK) Ltd is a private investment firm based in Hong Kong. The company focuses on managing investment funds and is known for its strategic investments in various sectors, including life sciences. The recent filing is part of their ongoing reporting obligations under the SEC regulations.

Forte Biosciences, Inc., the subject of this filing, is categorized under the Pharmaceutical Preparations SIC code [2834]. The company is headquartered in Dallas, Texas, and operates in a highly competitive industry where strategic investments and ownership stakes can significantly influence market dynamics.

What the Filing Says

The Schedule 13G/A filing states, "This Statement is filed on behalf of each of the following persons... Tybourne Capital Management (HK) Limited... This statement relates to securities previously held for the accounts of private investment funds... for which Tybourne HK serves as investment manager." The filing confirms that Tybourne has no voting or dispositive power over any shares of Forte Biosciences.

Impact

This update may affect various stakeholders, including investors and analysts who track Tybourne's investment strategies. The lack of ownership in Forte Biosciences could indicate a shift in focus for Tybourne, which may prompt competitors and other firms in the pharmaceutical sector to reevaluate their positions and strategies.

What's Next

The filing does not say what happens next regarding Tybourne's investment strategy or potential future actions concerning Forte Biosciences.